ABSTRACT
Recent years have seen major changes in the diagnostic use of genetics-based technologies. The current challenge is applying these technologies to improve treatment approaches in myeloma with the overall aim of individualizing myeloma therapy and improving patient survival. Although this is not feasible currently, within the next decade it is possible to see how strategies based on genetic technologies can be developed and applied in the clinical setting (see Table 11.1). Using these approaches, physicians will be able to not only predict outcome but also determine whether a patient will respond to a given treatment, an approach that is becoming more relevant with the introduction of effective new therapeutic agents.
